Immunotherapy drug- Durvalumab’s indication for the treatment of bladder cancer has been withdrawn in the US after it failed to improve survival.
Childhood Obesity May Up Risk of Bladder Cancer
Overweight and obesity during childhood can contribute to an increased burden of bladder cancer in adulthood. Therefore, following healthy lifestyle practices during childhood can reduce the risk of obesity in future.
Overweight and obesity during childhood can contribute to an increased burden of bladder cancer in adulthood. Therefore, following healthy lifestyle practices during childhood can reduce the risk of obesity in future.
‘Durvalumab is an immunotherapy drug approved for the treatment of extensive-stage small cell lung cancer. In the US, FDA has withdrawn Durvalumab’s indication for the treatment unresectable metastatic bladder cancer after it failed to improve survival.’
Read More..
The company will continue clinical trials of durvalumab in various combinations for the treatment of bladder cancer.Read More..
FDA has granted durvalumab accelerated approval in 2017 for the treatment of patients with locally advanced or metastatic urothelial carcinoma who experience disease progression during or following platinum-containing chemotherapy or who experience disease progression within 12 months of neoadjuvant or adjuvant treatment with that chemotherapy. In the phase 3 DANUBE trial conducted in patients with unresectable metastatic bladder cancer, neither durvalumab alone nor durvalumab plus tremelimumab improved survival when compared to the standard-of-care chemotherapy.
Dave Fredrickson, executive vice president, Oncology Business Unit, AstraZeneca, in a company press statement said, “ While the withdrawal in previously treated metastatic bladder cancer is disappointing, we respect the principles FDA set out when the accelerated approval pathway was founded."
Bladder Cancer – Symptoms, Signs, Diagnosis, Treatment, Prognosis & Prevention
Bladder cancer occurs due to abnormal cell growth in the urinary bladder. The most common kind usually is urothelial cancer or transitional cell carcinoma.
Bladder cancer occurs due to abnormal cell growth in the urinary bladder. The most common kind usually is urothelial cancer or transitional cell carcinoma.
Combination Biomarker Benefits Patients With Advanced Bladder Cancer
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors.
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors.
Immunotherapy Drug Avelumab Improves Survival in Advanced Bladder Cancer Patients
An immune drug avelumab has resulted in a survival advantage in bladder cancer, and will potentially benefit thousands of patients each year, said new study.
An immune drug avelumab has resulted in a survival advantage in bladder cancer, and will potentially benefit thousands of patients each year, said new study.
